苑东生物：布瑞哌唑片获得药品注册证书

Core Viewpoint - The approval of the drug Brupiprazole tablets by the National Medical Products Administration signifies compliance with drug registration requirements, although it is not expected to have a significant impact on the company's recent performance [1] Group 1: Drug Approval Details - The drug name is Brupiprazole tablets, available in dosages of 1mg, 2mg, and 4mg [1] - It is classified as a Class 4 chemical drug with a validity period of 12 months [1] - The active ingredient is Brupiprazole, indicated for the treatment of adult schizophrenia [1] Group 2: Impact on Company Performance - The approval of Brupiprazole tablets is not anticipated to have a major impact on the company's recent financial performance [1]